Leap Therapeutics, Inc. — Q1 2024 Form 10-Q
Filing identity: The filing is for Leap Therapeutics, Inc. (Nasdaq: LPTX), for the quarter ended March 31, 2024. This differs from the company name in the request metadata.
Business context and reporting period
Leap is a clinical-stage biopharmaceutical company developing antibody therapies for cancer. Its lead candidate is DKN-01, being studied in esophagogastric, gynecologic and colorectal cancers; FL-301 is its second clinical-stage program, with FL-302 and FL-501 in preclinical development. The company has no approved products and has generated no product-sales revenue. The financial statements are unaudited and cover the three months ended March 31, 2024, compared with the same period in 2023.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $11.3 million | $38.9 million |
| General and administrative expense | $3.5 million | $3.8 million |
| Total operating expenses | $14.8 million | $42.7 million |
| Net loss | $13.8 million | $41.9 million |
| Basic and diluted loss per share | $0.51 | $3.24 |
| Net cash used in operating activities | $15.5 million | $12.7 million |
| Cash and cash equivalents, quarter-end | $54.9 million | $102.0 million |
- Interest income was $0.8 million and Australian R&D incentive income was $0.2 million in Q1 2024. The filing reports no meaningful operating margin because Leap had no product revenue and incurred operating losses.
- At March 31, 2024, current assets were $56.2 million and current liabilities were $10.4 million. Total liabilities were $10.6 million, including $0.6 million in lease liabilities; the filing reports no borrowings or other financial debt.
- Stockholders’ equity was $47.4 million, down from $60.1 million at December 31, 2023, primarily reflecting the quarterly loss.
Material changes versus the prior comparable period
- Net loss fell by $28.0 million, chiefly because Q1 2023 included a $29.6 million noncash charge for acquired in-process research and development from the Flame transaction. The lower reported R&D expense therefore does not represent a comparable reduction in underlying program costs.
- DKN-01 direct R&D spending rose to $11.2 million from $9.3 million, while total R&D expense was $11.3 million. Management attributed the increase in program spending to higher clinical-trial costs and R&D payroll, partly offset by lower manufacturing and consulting costs.
- Operating cash use increased by $2.8 million year over year. Q1 2023 investing cash flows included $50.4 million of cash acquired with Flame; Q1 2024 had no investing cash flows.
- Cash declined by $15.7 million during Q1 2024. The quarter-end balance excludes the subsequent April financing.
Outlook, clinical updates and risks
- On April 15, 2024, Leap completed a private placement of common shares and pre-funded warrants, generating approximately $37.2 million in net proceeds. Management said the financing plus existing cash was expected to fund operating and capital expenditures into Q2 2026 and support expansion of the DKN-01 DeFianCe program. The filing’s liquidity note separately states that cash plus the financing should cover expenses for at least 12 months from issuance of the statements.
- In preliminary Part A DeFianCe data, among 27 response-evaluable patients with second-line advanced MSS colorectal cancer, reported overall response rate was 30%, disease control rate 93%, and median progression-free survival 6.3 months. These results are from a small study group and are not confirmation of efficacy in a randomized trial.
- DeFianCe Part B was expanded from 130 to 180 patients; 114 had enrolled as of May 8, 2024. Enrollment was expected to finish in late Q3 or early Q4 2024, with data expected in mid-2025. Part C of DisTinGuish completed enrollment of 170 patients; initial data were expected in the second half of 2024 or early 2025, when progression-free-survival data matured.
- Leap expects continued operating losses and may seek further financing, government support, or collaboration cost-sharing. If funding or tax-incentive receipts fall short, it may delay, reduce, or discontinue trials and R&D programs.
- Key risks include clinical-trial results and enrollment timing, regulatory approval, manufacturing and supply constraints, competition, intellectual-property protection, and the need for additional capital. DKN-01 and FL-301 are investigational and have not been approved by the FDA.
- The company reported no material legal proceedings, no material changes to internal control over financial reporting, and effective disclosure controls as of March 31, 2024.
Important facts for investors to verify
- Confirm the April 2024 financing terms, net proceeds, and fully diluted share count: the offering included 12.66 million common shares and pre-funded warrants for approximately 1.52 million shares.
- Assess cash burn and whether management’s runway estimate into Q2 2026 remains achievable as trial enrollment, costs, and financing needs evolve.
- Review the full DeFianCe and DisTinGuish data when available, including randomized comparisons, safety, patient populations, and maturity of follow-up.
- Distinguish the Q1 year-over-year expense decline from underlying operating trends, given the $29.6 million Flame-related acquired IPR&D charge in Q1 2023.
- Track potential dilution from outstanding options, warrants, and the April placement; the filing lists 8.7 million potential shares from options, RSUs, and warrants excluded from diluted loss-per-share calculations as anti-dilutive.